Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin

Cancer Biology and Therapy

Volumn 4, Issue 4, 2005, Pages 490-496

  Demidenko, Zoya N ^a   An, Won G ^b   Lee, John T ^c   Romanova, Larisa Y ^d   McCubrey, James A ^c   Blagosklonny, Mikhail V ^a,e  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Pusan National University   (South Korea)

^c EAST CAROLINA UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Bcr Abl; Chemotherapy; Geldanamycin; Hsp70; Hsp90; Imatinib; Leukemia; Raf 1

Indexed keywords

BCR ABL PROTEIN; GELDANAMYCIN; IMATINIB; PHOSPHOTRANSFERASE; RAF PROTEIN;

APOPTOSIS; ARTICLE; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION;

EID: 25144483367     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.4.1702     Document Type: Article

References (57)

1. 2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 1995; 86:1148-58.
2. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998; 91:1700-5.
3. Amarante-Mendes GP, Finucane DM, Martin SJ, Cotter TG, Salvesen GS, Green DR. Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Differ 1998; 5:298-306.
4. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91:2415-2422.
5. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-56.
6. Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with upregulation of Bcl-xL. Oncogene 1998; 16:1383-90.
7. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61:1799-804.
8. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005; 105:1246-55.
9. Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 1997; 17:5317-27.
10. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2:579-84.
11. Abe JI, Che W, Yoshizumi M, Huang Q, Glassman M, Ohta S, Wu Y, Arlinghaus R, Berk BC. Bcr in vascular smooth muscle cells involvement of Ras and Raf-1 activation by Bcr. Ann NY Acad Sci 2001; 947:341-3.
12. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, Calabretta B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998; 187:1995-2007.
13. Neshat MS, Raitano AB, Wang HG, Reed JC, CL S. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20:1179-86.
14. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18:189-218.
15. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 2003; 5:647-54.
16. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998; 5:710-715.
17. Oetzel C, Jonuleit T, Gotz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by downregulating BCL-X. Clin Cancer Res 2000; 6:1958-68.
18. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-posi-tive human leukemia cells to apoptosis due to antileukemia drugs. Blood 2000; 96:2246-53.
19. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537-43.
20. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-6.
21. Blagosklonny MV. Do cells need CDK2 and ...Bcr-Abl? Cell Death Differ 2004; 11:249-51.
22. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3-7.
23. Druker BJ. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21:239s-45s.
24. Druker BJ. Imatinib: Paradigm or Anomaly? Cell Cycle 2004; 3:833-5.
25. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
26. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-7.
27. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95:1758-66.
28. Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI 571: Diverse mechanisms of resistance. Blood 2000; 96:1070-9.
29. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95:3498-3505.
30. Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: Beyond STI571. Oncogene 2002; 21:8584-90.
31. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100:3041-4.
32. Daley GQ. Gleevec resistance: Lessons for target-directed drug development. Cell Cycle 2003; 2:190-1.
33. Daley GQ. Dodging the magic bullet: Understanding imatinib resistance. Cancer Biol Ther 2003; 2:109-10.
34. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-Mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996; 16:5839-45.
35. An WG, Schnur RC, Neckers LM, Blagosklonny MV. Depletion of ErbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997; 40:60-4.
36. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: Role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated downregulation of Akt, Raf-1, and Src kinases. Blood 2003; 102:269-75.
37. An WG, Schulte TW, Neckers LM. The HSP90 antagonist geldanamycin alters chaperone association with p210BCR-ABL and v-src proteins prior to their degradation by the proteasome. Cell Growth Diff 2000; 11:355-60.
38. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12:1903-29.
39. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3:372-9.
40. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64:3653-60.
41. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: Identification of an Achilles heel in leukemia. Leukemia 2003; 1:1058-67.
42. Chang F, Steelman LS, McCubrey JA. Rat-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002; 1:220-6.
43. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J, Neckers L. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56:1851-4.
44. Stiewe T, Parssanedjad K, Esche H, Opalka B, Putzer BM. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res 2000; 60:3957-64.
45. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI 571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15:342-7.
46. Zheng TS, Hunot S, Kuida K, Momoi T, Srinivasan A, Nicholson D, Lazebnik Y, Flavell RA. Deficiency in caspase-9 or caspase-3 induces compensatory caspase activation. Nat Med 2000; 6:1241-7.
47. MacFarlane M. Compensatory caspase activation: A cautionary tale. Trends Pharmacol Sci 2001; 22:60.
48. Shah N, Asch RJ, Lysholm AS, LeBien TW. Enhancement of stress-induced apoptosis in B-lineage cells by caspase-9 inhibitor. Blood 2004; 104:2873-8.
49. Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 2004; 24:10289-99.
50. Blagosklonny MV. STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 2002; 16:570-2.
51. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105:1768-76.
52. Topaly J, Schad M, Laufs S, Melo JV, Zeller WJ, Fruehauf S. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL. Br J Haematol 2003; 121:672-3.
53. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103:208-15.
54. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101:690-8.
55. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64:672-7.
56. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279:34227-39.
57. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: Implications, problems and solutions. Cell Cycle 2004; 3:1537-42.